Nevin Manimala Statistics

AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials

Pharm Stat. 2022 Nov 5. doi: 10.1002/pst.2272. Online ahead of print.


Designing Phase I clinical trials is challenging when accrual is slow or sample size is limited. The corresponding key question is: how to efficiently and reliably identify the maximum tolerated dose (MTD) using a sample size as small as possible? We propose model-assisted and model-based designs with adaptive intrapatient dose escalation (AIDE) to address this challenge. AIDE is adaptive in that the decision of conducting intrapatient dose escalation depends on both the patient’s individual safety data, as well as other enrolled patient’s safety data. When both data indicate reasonable safety, a patient may perform intrapatient dose escalation, generating toxicity data at more than one dose. This strategy not only provides patients the opportunity to receive higher potentially more effective doses, but also enables efficient statistical learning of the dose-toxicity profile of the treatment, which dramatically reduces the required sample size. Simulation studies show that the proposed designs are safe, robust, and efficient to identify the MTD with a sample size that is substantially smaller than conventional interpatient dose escalation designs. Practical considerations are provided and R code for implementing AIDE is available upon request.

PMID:36333972 | DOI:10.1002/pst.2272

By Nevin Manimala

Portfolio Website for Nevin Manimala